Wellgistics Health, INC 8-K filings

Wellgistics Health announced a partnership with DataVault AI to develop PharmacyChain, a blockchain-enabled platform for prescription drug tracking and data monetization, with beta testing expected in the first half of 2026.

Wellgistics Health and DataVault AI announce a non-binding LOI to integrate blockchain-enabled smart contracts for prescription drug tracking.

Wellgistics Health, Inc. announced significant executive management and Board of Directors changes, including the re-appointment of Prashant Patel as President and Interim-CEO.

Wellgistics Health, Inc. announced the simultaneous resignations of its Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, followed by the appointment of an interim Chief Financial Officer.

Wellgistics Health, Inc. announced a significant board restructuring, including director removals and resignations, alongside the appointment of a new President.

Wellgistics Health completed a $5 million public offering and announced a strategic collaboration with TheracosBio to expand access to an FDA-approved diabetes therapy.

Wellgistics Health, Inc. announced it will present at three investor conferences in September 2025 and released an updated corporate presentation and fact sheet.

Wellgistics Health secured a $1.3 million business loan and introduced HubRx AI, a new customizable artificial intelligence engine to streamline prescription services.

Wellgistics Health announced its second fiscal quarter 2025 financial results, showing revenue stability and significant progress on operational, governance, and growth initiatives since its February 2025 IPO.

Wellgistics Health announced the termination of its $50 million equity line of credit and the launch of a blockchain-based XRP payment program for pharmacies.

Wellgistics Health, Inc. announced the conversion of $8.1 million in debt to equity and an increase in promissory notes to $17.5 million, aiming to strengthen its balance sheet and improve cash flow.

Wellgistics Health, Inc. has announced the dismissal of its independent registered public accounting firm, Suri & Co., and the engagement of UHY LLP, following Suri's previous reports that included a going concern note.

Wellgistics Health, Inc. releases a revised investor presentation on May 15, 2025, outlining its projects, potential financial performance, and growth opportunities.

Wellgistics Health, Inc. announced the appointment of Mark DiSiena as its new Chief Financial Officer, effective April 22, 2025, succeeding Vishnu Balu.

Wellgistics Health's CEO, Brian Norton, converts $1.5 million debt into equity, signaling confidence in the company's future.

Wellgistics Health, Inc. announces a definitive agreement to acquire Peek Healthcare Technologies, Inc., a digital prescription shopping platform, to enhance its healthcare technology and pharmaceutical services.

Wellgistics Health grants significant stock awards and releases a letter from the CEO highlighting 2024 achievements and future growth plans, including acquisitions and AI-driven solutions.

Wellgistics Health enters a consulting agreement with Draper, Inc. for investor relations and business development services, and announces successful completion of a third-party audit for SOC 2 Type 1 compliance.

Wellgistics Health, Inc. announces the promotion of Brian Norton to CEO and a collaboration with Protega Pharmaceuticals to support pharmacist education and patient access to abuse-deterrent opioid ROXYBOND.

Wellgistics Health, Inc. has entered into a consulting agreement with Hudson Global Ventures, LLC and partnered with Tollo Health, LLC to market medical food products for GLP-1 treatment side effects and Long COVID.

Wellgistics Health, Inc. has successfully launched its initial public offering, raising $4 million to fuel its healthcare technology and pharmaceutical services initiatives.